Preclinical evidence and clinical data demonstrated the robust activity of pyrotinib inhibiting the proliferation of HER2-overexpressing breast tumors and the favorable efficacy of antitumor (16, 17, 19, 20). This evidence concerns the gene ERBB2 and breast neoplasm.